Compare Abbott Laboratories (ABT) vs Goodyear Tire & Rubber Co (GT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Goodyear Tire & Rubber Co — how do they compare? Abbott Laboratories trades at $95.31 (market cap $166.94B), while Goodyear Tire & Rubber Co trades at $6.54 (market cap $2.02B). The key difference: Abbott Laboratories is far larger — about 82.6× Goodyear Tire & Rubber Co's market cap, and Abbott Laboratories pays a 2.63% dividend while Goodyear Tire & Rubber Co pays none. Which is the better fit depends on your goals.
| ABT | GT | |
|---|---|---|
Market Cap | $166.94B | $2.02B |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $11.55 |
52-Week Low | $82.57 | $5.58 |
Enterprise Value | $193.69B | $9.33B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Goodyear Tire & Rubber (GT) trades at $7.02, up 6.53% today, with a bullish technical signal from moving averages and oscillators. The stock shows deep value metrics with P/E of 4.69 and P/B of 0.66, but faces profitability challenges with negative net income margin of -11.64% and ROE of -52.56%. Recent developments include the company's move to the S&P SmallCap 600 and new NASA lunar tire contract, while Q1 2026 earnings beat estimates despite a net loss.
The outlook remains mixed with analyst consensus at Buy (34.62%) and price target of $8.80 offering 25% upside, but persistent operational headwinds and declining revenue trends pose significant risks. Investment opportunity lies in valuation discount and Goodyear Forward program benefits, though weak tire volumes and negative cash flow projections for 2026 require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →
